The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...
Receipt of a cardiac-resynchronization therapy-defibrillator (CRT-D) offers long term benefit for patients with heart failure, reduced ejection fraction, and a widened QRS complex, according to a ...
The 2025 Appropriate Use Criteria for implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy (CRT), and pacing have been released. This year’s guideline is broader than ...
SUNNYVALE, Calif.--(BUSINESS WIRE)--EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced the publication of a case report demonstrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results